I am eagerly anticipating the upcoming 2018 ISPE Continuous Manufacturing Workshop to be held June 6 & 7th in Arlington, Virginia immediately following the 2018 ISPE Quality Manufacturing Conference. This workshop will provide a snapshot of today’s landscape for continuous pharmaceutical manufacturing of small molecules drug substances and drug products, and examine the ongoing and future activities to further progress the field. The content will be informative to both experts and novices in the field and will cover all major aspects of continuous manufacturing including development, quality assurance, regulatory, and manufacturing. I consider it to be a great honor to be the chair of such an important event around a technology that could revolutionize pharmaceutical manufacturing.
In the past 2 years, since the first ISPE Continuous Manufacturing Workshop, several advances have been made in the field, including:
The transition from batch manufacturing has not necessarily been an easy one, with the first practitioners overcoming equipment issues, an unknown regulatory landscape, and organizational biases of “we’ve always done batch”. We anticipate that attendees will walk away from these two days better equipped to deal with the technical, regulatory, and organizational challenges associated with implementing this new technology.
The 2018 ISPE Continuous Manufacturing Workshop will bring together the early adopters of the technology to share their learnings from implementing continuous manufacturing for pharmaceutical drug substances and drug products. In addition to traditional podium sessions, the lineup includes several interactive round table discussions where panels of industry experts and regulators will share their experiences and answer questions from the audience. We have also included academics who will share the exciting contributions and future directions of the dozens of universities involved in continuous pharmaceutical manufacturing research.
All in all, I think we have a tremendous line up of sessions and speakers that will enhance all attendees’ knowledge of continuous pharmaceutical manufacturing. I hope to see you in June at the workshop!
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...
